Dyax Corp. to Host First Quarter 2014 Earnings Call and Webcast
Business Wire - Thu Apr 17, 7:00AM CDT
Dyax Corp. (NASDAQ
Dyax Corp. Announces Appointment of Todd Bazemore as Chief Commercial Officer
Business Wire - Wed Apr 16, 7:01AM CDT
Dyax Corp. (NASDAQ: DYAX) announced today the appointment of Todd Bazemore as Executive Vice President and Chief Commercial Officer. Mr. Bazemore will be responsible for leading Dyax's commercial organization which currently markets KALBITOR(R) (ecallantide) for the treatment of acute attacks of hereditary angioedema (HAE) in patients 12 years of age and older.
The Recent Performance of 'Baker Brother Biotech Stocks' is Awful
at The Street - Tue Apr 15, 11:23AM CDT
Healthcare's most closely followed hedge fund is losing money during the biotech bubble burst.
Downtrend Call Working As Dyax Stock Falls 15.0% (DYAX)
Comtex SmarTrend(R) - Mon Apr 14, 9:18AM CDT
SmarTrend identified a Downtrend for Dyax (NASDAQ
Dyax wins FDA approval to include use of KALBITOR for treating HAE acute attacks in patients 12 years of age and older
M2 - Fri Apr 04, 6:08AM CDT
Biopharmaceutical company Dyax (NasdaqGM
Dyax Receives FDA Approval to Expand Use of KALBITOR(R) (ecallantide) for the Treatment of Acute Attacks of Hereditary Angioedema to Patients 12 Years of Age and Older
Business Wire - Thu Apr 03, 3:05PM CDT
Dyax Corp. (NASDAQ
Dyax Corp. to Participate in the 13th Annual Needham Healthcare Conference
Business Wire - Wed Apr 02, 1:00PM CDT
Dyax Corp. (NASDAQ: DYAX) announced today that executive management will participate in the 13th Annual Needham Healthcare Conference being held April 8-9, 2014 at the Westin Grand Central Hotel in New York City. Gustav Christensen, President and Chief Executive Officer of Dyax, will present on Tuesday, April 8 at 2:20 PM (ET). Mr. Christensen will provide a corporate update on the Company's key value drivers - the KALBITOR(R) (ecallantide) business, DX-2930 and the Licensing and Funded Research Portfolio.
Dyax Corp. (DYAX) in Focus: Stock Up 6% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Apr 01, 7:44AM CDT
Dyax Corp. was a big mover last session, as the company saw its shares rally nearly 6% on the day.
Dyax Corporation (DYAX) Marked As A Dead Cat Bounce Stock
at The Street - Thu Mar 27, 9:07AM CDT
Trade-Ideas LLC identified Dyax Corporation (DYAX) as a "dead cat bounce" (down big yesterday but up big today) candidate
Dyax reports full exercise of 1.2m additional shares in underwriters' option
M2 - Wed Mar 26, 3:01AM CDT
Biopharmaceutical company Dyax (NasdaqGM
Dyax Announces Full Exercise of Underwriters' Option to Purchase Additional Shares
Business Wire - Tue Mar 25, 3:05PM CDT
Dyax Corp. (NASDAQ: DYAX) today announced that the underwriters of its previously announced public offering have exercised in full their option to purchase an additional 1,200,000 shares of Dyax's common stock at a price to the public of $9.25 per share, less customary underwriting discounts and commissions. The net proceeds of approximately $10.4 million from the exercise of the option brings the aggregate net proceeds from the offering to approximately $80.0 million, after deducting the underwriting discount and other estimated offering expenses payable by Dyax. The additional shares were delivered to the underwriters on March 25, 2014.
Shares of DYAX Up 13.8% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Thu Mar 20, 10:06AM CDT
SmarTrend identified an Uptrend for Dyax (NASDAQ
Dyax prices public offering of 8m common shares
M2 - Mon Mar 17, 9:39AM CDT
US-based biopharmaceutical company Dyax (NasdaqGM
Nasdaq stocks posting largest percentage decreases
AP - Fri Mar 14, 5:06PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
Why Dyax Corp. Shares Dipped
Sean Williams, The Motley Fool - Motley Fool - Fri Mar 14, 12:24PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Dyax , a biopharmaceutical company focused...
Dyax Announces Pricing of $74 Million Public Offering of Common Stock
Business Wire - Fri Mar 14, 8:05AM CDT
Dyax Corp. (NASDAQ: DYAX) today announced the pricing of an underwritten public offering of 8,000,000 shares of its common stock, offered at a price to the public of $9.25 per share. The gross proceeds to Dyax from this offering are expected to be $74 million, before deducting the underwriting discounts and commissions and other estimated offering expenses payable by Dyax. The offering is expected to close on or about March 19, 2013, subject to customary closing conditions.
Dyax to sell common stock in planned public offering
M2 - Fri Mar 14, 3:50AM CDT
Biopharmaceutical company Dyax (NasdaqGM
Dyax Announces Proposed Public Offering of Common Stock
Business Wire - Thu Mar 13, 3:02PM CDT
Dyax Corp. (NASDAQ: DYAX) today announced that it is offering to sell shares of its common stock in a proposed underwritten public offering. All shares to be sold in the offering are being sold by Dyax. The offering is subject to market and other conditions and there can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the offering. Jefferies LLC is acting as the sole book-running manager for the offering. Cowen and Company, LLC is acting as the co-lead manager, with Wedbush PacGrow Life Sciences, Needham & Company, LLC, and Oppenheimer & Co. Inc. acting as co-managers.
27.7% Return Seen to Date on SmarTrend Dyax Call (DYAX)
Comtex SmarTrend(R) - Wed Mar 12, 5:05PM CDT
SmarTrend identified an Uptrend for Dyax (NASDAQ